

Helix BioMedix Bolsters Management Team

Feb 04, 2004 - Bothell, Washington

Helix BioMedix (OTC BB: HXBM.OB) announced today that David Drajeske has joined the company as Director of Business Development and David Kirske has joined the company as Vice President – Finance and Administration. Mr. Drajeske previously served as Manager of Business Development for Amgen where his responsibilities included the identification of and negotiating with partners for licensing, collaboration and manufacturing agreements. Mr. Drajeske holds a Master of Science degree in Biotechnology from Northwestern University's Kellogg Center for Biotechnology.

David Kirske has served in senior level financial positions at several high growth companies, such as F5 Networks, Inc. and Redhook Ale Brewery. Mr. Kirske has broad business transaction experience which includes venture financing, public equity offerings, joint venture licensing arrangements, and mergers and acquisitions. Mr. Kirske's experience also includes successfully leading human resources, facilities and information technology teams for growth-stage companies.

"We are extremely pleased to have executives of the caliber of Mr. Kirske and Mr. Drajeske join our senior management team to support our transition from an early-stage status to a revenue-generating company" stated R. Stephen Beatty, President and CEO. "This year, we have reached an inflexion point where we anticipate that our ongoing discussions will result in revenue generating agreements from the licensing of our peptide based technology."

The company also announced that the Governance Committee of its Board of Directors has initiated a nation-wide search for board candidates who possess backgrounds that are synergistic with the company's consumer products initiatives. The company is currently in discussions with several Fortune 500 companies regarding the potential out-licensing of certain proprietary peptides for consumer products.

About Helix BioMedix:

Helix BioMedix, Inc. is an early-stage biotechnology company whose mission is to become the industry leader in developing and commercializing bioactive peptides (small proteins). The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as pharmaceutical agents for use in treating cystic fibrosis, sexually-transmitted diseases, and in wound healing. Non-pharmaceutical applications being pursued include adjuvants for cosmetics/cosmeceuticals and wide-spectrum biocides. More information about the company can be found on the company's website at www.helixbiomedix.com.

Statements made in this press release relating to Helix BioMedix's future growth potential are forward-looking and actual results could differ materially. Among other things, Helix BioMedix's future growth potential could be impacted by a number of factors, including competition, pricing, reimbursement, the ability to supply product, product withdrawals, new product approvals and launches, unanticipated expenses such as litigation or legal settlement expenses or equity securities writedowns, costs of sales, R&D expenses, fluctuations in contract revenues and royalties, and fluctuations in tax and interest rates.

For more information, please contact:
R. Stephen Beatty President and CEO
(425) 402-8400
sbeatty@helixbiomedix.com.